Document Detail

Hypertension costs: source, evolution and impact of cost-containment measures in various health-care systems.
MedLine Citation:
PMID:  2791324     Owner:  NLM     Status:  MEDLINE    
As a consequence of the high prevalence of hypertension in most countries, the management of this disease generates costs which are only justified if the beneficial effects of the reduced blood pressure can be achieved by the long-term control of blood pressure in compliant patients. The expenditure includes not only the cost of drugs, but also the cost of visits to physicians and various supplementary examinations. Whereas these latter cost items are exclusively dependent on the physicians who order them, the costs of the drugs are dependent on the physician's choice and also on the drug-pricing mechanisms, which are complex, variable from one country to another and dependent on economic choices, as well as on medical parameters. The selection of drugs should be tailored to each individual patient and based on reliable medical evidence. However, the consequences of the choice of drugs will be very much influenced by the pricing procedures applied in each country. Whereas improvement in the quality of hypertension management will increase the efficacy of the medical intervention, cost-containment measures might make it even more efficient. These measures can be initiated by the physicians themselves, in regard to the number of visits and the choice of supplementary examinations. They can also be generated by incentive measures coming from the different health-care systems (state or private insurance schemes). Such measures should prevent patients being deprived of access to the most modern methods of treatment, including examinations and drugs, while at the same time aiming at eliminating unnecessary examinations and inappropriate choice of drugs. The impact of cost-containment measures, when implemented, should be monitored in regard to both the quality of care (permanent blood pressure control of treated patients, without impairment of their quality of life) and the existence of social inequalities in the access to optimal health-care.
J Ménard
Related Documents :
16168164 - Implementing a teledermatology programme.
17200594 - The cost of schizophrenia: lessons from an international comparison.
9550954 - Is day care equivalent to inpatient care for active rheumatoid arthritis? randomised co...
15866794 - Cost-effectiveness: seeking value for money in lower extremity wound management.
6846584 - The significance of ritual in a church-based healing model.
18377334 - Haemorrhagic shock therapy.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical and experimental hypertension. Part A, Theory and practice     Volume:  11     ISSN:  0730-0077     ISO Abbreviation:  Clin Exp Hypertens A     Publication Date:  1989  
Date Detail:
Created Date:  1989-11-06     Completed Date:  1989-11-06     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  8207790     Medline TA:  Clin Exp Hypertens A     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1149-69     Citation Subset:  IM    
International Clinical Research & Development, CIBA-GEIGY Limited, Basle.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use
Cost Control
Costs and Cost Analysis
Delivery of Health Care / economics
Developing Countries
Drug Prescriptions / economics
Health Maintenance Organizations / economics
Hypertension / economics*,  therapy
Office Visits / economics
Patient Participation
Reg. No./Substance:
0/Antihypertensive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The INTERSALT study: main results, conclusions and some implications.
Next Document:  Public health measures for blood pressure control in the whole community.